|
US2021024601A1
|
|
Interleukin-2 agents and uses thereof
|
|
US2020392241A1
|
|
Humanized antibody molecules to cd138 and uses thereof
|
|
US2020308257A1
|
|
Compositions and methods for treating and preventing influenza
|
|
WO2020139834A1
|
|
Methods for identifying epitopes and paratopes
|
|
AU2018345637A1
|
|
Antibody molecules to CD138 and uses thereof
|
|
CN110431150A
|
|
Antibody molecule-drug conjugates and application thereof
|
|
MX2019007356A
|
|
Binding polypeptides and methods of making the same.
|
|
AU2017325654A1
|
|
Engineered polypeptides and uses thereof
|
|
WO2017181098A2
|
|
Antibody molecules to zika virus and uses thereof
|
|
CA3018216A1
|
|
Formulations of antibody molecules to dengue virus
|
|
AU2017222564A1
|
|
Formulations of antibody molecules to influenza virus
|
|
CN109089419A
|
|
The antibody molecule of APRIL and its application
|
|
EP3374390A1
|
|
Compositions and methods for treating and preventing influenza
|
|
AU2016353073A1
|
|
Antibody molecule-drug conjugates that specifically binds to lipopolysaccharide and uses thereof
|
|
US2015225474A1
|
|
Antibody molecules to dengue virus and uses thereof
|
|
BR112016018372A2
|
|
Dengue virus antibody molecules and their uses
|
|
EP3016685A1
|
|
Synthetic oligosaccharides for p. aeruginosa vaccine
|
|
EP2884842A1
|
|
Synthetic oligosaccharides for p. aeruginosa vaccine
|
|
US2013302349A1
|
|
HA binding agents
|
